Roderick L. Beijersbergen, Ph.D., The Netherlands Cancer Institute
Michael Boutros, Ph.D., German Cancer Research Center (invited)
Christophe J. Echeverri, Ph.D., Cenix BioScience GmbH
Stephen J. Elledge, Ph.D., Harvard Medical School
Marc Ferrer, Ph.D., Merck & Co.
Alex Gaither, Ph.D., Novartis Institutes for Biomedical Research
Richard Janssen, Ph.D., BioFocus DPI, A Galapagos Company
Paul D. Kassner, Ph.D., Amgen Inc.
Xiaoyu Lin, Ph.D., Abbott Laboratories
Nikolaus Machuy, Ph.D., Max-Planck Institute for Infection Biology
Jeff MacKeigan, Ph.D., Van Andel Research Institute
Muthiah Manoharan, Ph.D., Alnylam Pharmaceuticals
Ian McLachlan, Ph.D., Protiva Biotherapeutics (invited)
Norbert Perrimon, Ph.D., Harvard Medical School
Quick Que, Ph.D., Translational Genomics Research Institute
Michael White, Ph.D., University of Southwestern Medical Center
Thomas Singer D.A.B.T., Global Head of Non-Clinical Safety, F. Hoffmann-La Roche AG
Elena Feinstein, M.D., Chief Scientific Officer, Quark Pharmaceuticals Inc.
Steven C. Quay, M.D., Ph.D., Chairman and Chief Scientific Officer, MDRNA Inc.
Tod Woolf, Ph.D., President and Chief Executive Officer, RXi Pharmaceuticals
Klaus Giese, Ph.D., Chief Scientific Officer, Silence Therapeutics PLC
.jpg "TVD RB")
.jpg "HDAC RB")
